TheStreet upgraded shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) from a c+ rating to a b- rating in a research note published on Monday morning.

Several other analysts have also recently commented on the company. Deutsche Bank AG reiterated a buy rating and set a $255.00 price target on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. Zacks Investment Research upgraded Bio-Rad Laboratories from a sell rating to a hold rating in a research report on Wednesday, October 4th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Bio-Rad Laboratories has an average rating of Buy and a consensus price target of $260.00.

Shares of Bio-Rad Laboratories (NYSE BIO) opened at $254.14 on Monday. The company has a market capitalization of $7,540.54, a P/E ratio of 80.77, a PEG ratio of 3.84 and a beta of 0.88. Bio-Rad Laboratories has a 12-month low of $169.19 and a 12-month high of $268.40. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.06 and a quick ratio of 2.77.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.37. The business had revenue of $535.00 million during the quarter, compared to analysts’ expectations of $507.99 million. Bio-Rad Laboratories had a return on equity of 3.44% and a net margin of 1.15%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 earnings per share. sell-side analysts anticipate that Bio-Rad Laboratories will post 2.65 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/16/bio-rad-laboratories-inc-bio-raised-to-b-at-thestreet.html.

In other Bio-Rad Laboratories news, EVP Giovanni Magni sold 2,400 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $253.01, for a total transaction of $607,224.00. Following the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at $2,340,595.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 28.29% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Canada Pension Plan Investment Board acquired a new position in Bio-Rad Laboratories during the second quarter worth $113,000. Pacad Investment Ltd. acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $113,000. First Manhattan Co. lifted its stake in shares of Bio-Rad Laboratories by 71.6% in the 3rd quarter. First Manhattan Co. now owns 599 shares of the medical research company’s stock valued at $133,000 after purchasing an additional 250 shares during the last quarter. Turner Investments LLC acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $136,000. Finally, Meeder Asset Management Inc. lifted its stake in shares of Bio-Rad Laboratories by 3,333.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 618 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 600 shares during the last quarter. 64.27% of the stock is currently owned by institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.